1. Signaling Pathways
  2. Protein Tyrosine Kinase/RTK
  3. c-Fms

c-Fms

CSF-1 receptor; colony stimulating factor 1 receptor; CSF-1R; CSF1R

c-FMS (CSF1R, CSF-1R) is a receptor protein-tyrosine kinase of the platelet-derived growth factor receptor (PDGFR) family. c-FMS is the cell surface receptor for IL-34 and CSF1. c-FMS has important roles in haematopoiesis, regulation of proliferation, cell survival and maturation of microglia and monocytes, as well as in controlling the overall immune response.

c-FMS is specifically expressed in osteoclasts and myelomonocytic-lineage cells, such as monocytes and macrophages, and the activation of c-FMS signaling promotes the proliferation or differentiation of these cells. It also promotes the production of inflammatory mediators, such as tumor necrosis factor-alpha (TNF-α) and interleukin 6 (IL6).

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-101768
    PRN1371
    Inhibitor 99.78%
    PRN1371 is a highly selective and potent FGFR1-4 and CSF1R inhibitor with IC50s of 0.6, 1.3, 4.1, 19.3 and 8.1 nM for FGFR1, FGFR2, FGFR3, FGFR4 and CSF1R, respectively.
    PRN1371
  • HY-109190
    Seralutinib
    Inhibitor 99.94%
    Seralutinib (GB002) is an inhaled PDGFRα and PDGFRβ inhibitor. Seralutinib also targets to CSF1R and c-KIT with IC50s of 8 nM and 14 nM, respectively. Seralutinib (GB002) is used in the study for pulmonary arterial hypertension.
    Seralutinib
  • HY-10204
    OSI-930
    Inhibitor 98.33%
    OSI-930 is an orally selective inhibitor of Kit, KDR and CSF-1R (c-Fms) with IC50s of 80 nM, 9 nM and 15 nM, respectively. OSI-930 also moderately inhibits Flt-1, c-Raf, Lck and low activity against PDGFRα, Flt-3 and Abl. OSI-930 has antitumor activity.
    OSI-930
  • HY-P99259
    Cabiralizumab
    Inhibitor 99.73%
    Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research.
    Cabiralizumab
  • HY-153920
    Pimicotinib
    Inhibitor 99.92%
    Pimicotinib (ABSK021) is a selective and orally active CSF1R inhibitor with an IC50 value of 19.48 nM (determined by inhibiting ADP production). Pimicotinib exhibits anti-tumor activity.
    Pimicotinib
  • HY-101774
    CSF1R-IN-1
    Inhibitor 98.04%
    CSF1R-IN-1 is a CSF1R inhibitor with an with an IC50 of 0.5 nM.
    CSF1R-IN-1
  • HY-124526
    Chiauranib
    Inhibitor 99.28%
    Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1, VEGFR2, VEGFR3, PDGFRα and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R, with IC50 values ranging from 1-9 nM. Chiauranib has strongly anticancer effects.
    Chiauranib
  • HY-13838
    PLX647
    Inhibitor 99.74%
    PLX647 is an orally active, highly specific dual FMS and KIT kinase inhibitor, with IC50s of 28 and 16 nM, respectively. PLX647 shows selectivity for FMS and KIT over a panel of 400 kinases at a concentration of 1 μM except FLT3 and KDR (IC50s=91 and 130 nM, respectively).
    PLX647
  • HY-161025
    SYHA1813
    Inhibitor 99.46%
    SYHA1813 is a dual inhibitor of CSF1R and VEGFR. SYHA1813 has potent antitumor activity against GBM.
    SYHA1813
  • HY-10408
    Ki20227
    Inhibitor 99.51%
    Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC50s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2 (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor receptor β). Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction.
    Ki20227
  • HY-P990125
    Anti-Mouse CSF1R/CD115 Antibody (AFS98)
    99.38%
    Anti-Mouse CSF1R/CD115 Antibody (AFS98) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse CSF1R.
    Anti-Mouse CSF1R/CD115 Antibody (AFS98)
  • HY-P99452
    Axatilimab
    Inhibitor 99.59%
    Axatilimab (SNDX-6352) is a humanized IgG4 antibody with high affinity to CSF-1R. Axatilimab can be used for the research of chronic graft versus host disease (cGVHD) and neoplastic diseases.
    Axatilimab
  • HY-P99795
    Otilimab
    Inhibitor
    Otilimab (GSK 3196165) is an anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) human monoclonal antibody. Otilimab neutralises the biological function of GM-CSF by blocking the interaction of GM-CSF with its cell surface receptor.
    Otilimab
  • HY-136362
    ARRY-382
    Inhibitor 99.63%
    ARRY-382 is a potent, oral and highly selective inhibitor of CSF1R/c-Fms with an IC50 of 9 nM. ARRY-382 can be used for the research of advanced or metastatic cancers.
    ARRY-382
  • HY-117244
    AZD7507
    Inhibitor 99.57%
    AZD7507 is a potent and orally active CSF-1R inhibitor, with antitumor activity.
    AZD7507
  • HY-P990094
    Trabikibart
    99.17%
    Trabikibart (CSL311), a βc (CSF2RB)-specific, fully human monoclonal antibody, binds to a unique epitope that is specific to the cytokine-binding site of the human βc receptor. Trabikibart has picomolar binding affinity for the human βc receptor. Trabikibart is a potent inhibitor of the combined effects of IL-3, GM-CSF and IL-5 on the survival of eosinophils. Trabikibart has the potential for chronic inflammatory diseases research.
    Trabikibart
  • HY-18791
    c-Fms-IN-1
    Inhibitor 99.97%
    c-Fms-IN-1 is a FMS kinase inhibitor with an IC50 of 0.0008 μM.
    c-Fms-IN-1
  • HY-159108
    AZ683
    Inhibitor 98.57%
    AZ683 is a potent and selective 3-amido-4-anilinoquinoline CSF1R inhibitor. AZ683 has high affinity for CSF1R (Ki=8 nM; IC50=6 nM). AZ683 has good oral bioavailability. [11C]AZ683 can be used as a positron emission tomography (PET) radiotracer for colony stimulating factor 1 receptor (CSF1R).
    AZ683
  • HY-122906
    JTE-952
    Inhibitor 99.95%
    JTE-952 is a potent, oral active and selective Type II inhibitor of colony stimulating factor-1 receptor (CSF-1R or cFMS, type III receptor tyrosine kinase), with IC50 values of 13 nM and 261 nM for CSF1R and TrkA , respectively. Effective against a mouse collagen-induced model of arthritis.
    JTE-952
  • HY-139990
    CSF1R-IN-3
    Inhibitor 98.26%
    CSF1R-IN-3 (compound 21) is a potent and orally active CSF-1R inhibitor (IC50=2.1 nM). CSF1R-IN-3 is a potent antiproliferative activity against colorectal cancer cells. CSF1R-IN-3 inhibits the progression of colorectal cancer by suppressing the migration of macrophages, reprograming M2-like macrophages to the M1 phenotype, and enhancing the antitumor immunity.
    CSF1R-IN-3
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity